Your wrist-based smartwatch is a genuinely useful tool. But when your cardiologist asks you to bring in a heart recording — something they can actually read, annotate, and file in your chart — the odds are high that your Apple Watch’s PDF won’t be what they had in mind. That gap between “consumer heart monitoring” and “clinically accepted ECG recording” is what this article is about. An ECG (electrocardiogram) is a graph of the electrical signals your heart produces with every beat. The key word in “FDA-cleared portable ECG” is cleared: it means the U.S. Food and Drug Administration has reviewed that specific device and determined it produces medically reliable data for a stated purpose — typically detecting atrial fibrillation (AFib), an irregular heart rhythm that affects roughly 6 million Americans and dramatically raises stroke risk, per the American Heart Association’s AFib patient resources. What you’ll get from this guide is a direct comparison of the devices that actually meet that bar, the tradeoffs between them, and a clear decision rule at the end.
Why “FDA-Cleared” Is the Only Label That Matters Here
The consumer wearable market is crowded with devices that detect heart rate and even display something labeled “ECG.” Very few of them carry the FDA clearance that makes a recording clinically actionable. Understanding the distinction saves you money, time, and a frustrating conversation with your cardiologist.
The three tiers of cardiac monitoring, briefly:
- Optical heart-rate sensors (most smartwatch wristbands): use light to estimate heart rate. Fast, comfortable, continuous — but the output is heart rate, not a waveform. Cannot detect arrhythmia morphology.
- Single-lead electrical ECG (KardiaMobile, Apple Watch ECG app, Samsung Galaxy Watch ECG): capture a true electrical signal from two contact points. Sufficient for AFib detection. Apple Watch and Samsung Galaxy Watch have received FDA clearance for their ECG apps specifically, though the recording format and cardiologist acceptance varies significantly by practice.
- Multi-lead electrical ECG (KardiaMobile 6L, Wellue DuoEK, Emay EMG-10): capture signals from more than one electrical “view” of the heart. Closer to what a hospital 12-lead ECG produces. Substantially higher diagnostic value for complex arrhythmias.
The FDA’s De Novo and 510(k) database (maintained at fda.gov) is the authoritative record. A device either has a clearance number on file or it doesn’t — marketing language about “medical grade” or “clinical accuracy” means nothing without it.
One practical note on smartwatches: Apple Watch Series 4 and later received FDA clearance for their ECG app for AFib detection. That clearance is real. The complication is that many cardiologists prefer the KardiaMobile or Emay format because the PDF output is structured to match clinical reporting conventions. Per Wareable’s review of the AliveCor KardiaMobile 6L, the device’s PDF output is explicitly designed for cardiologist review — which is a product decision, not just a spec.
The Devices Cardiologists Are Most Likely to Accept
AliveCor KardiaMobile 6L (~$149 at retail)
The 6L is the benchmark in this category for a specific reason: it captures six leads simultaneously (leads I, II, III, aVL, aVR, aVF) using a palm-and-knee contact method with a credit-card-sized device. That six-lead output is meaningful because it gives a cardiologist multiple electrical views — the same views they’d see on a partial hospital ECG — rather than a single-lead strip.
FDA clearance status: Yes. The KardiaMobile 6L holds FDA 510(k) clearance and is the only FDA-cleared personal ECG device explicitly cleared for detecting AFib, bradycardia, tachycardia, and normal sinus rhythm, per AliveCor’s published FDA clearance documentation.
What cardiologists actually receive: A PDF report with a standard ECG grid, AliveCor’s AI interpretation (labeled as such), and a timestamp. PCMag’s roundup of best ECG monitors notes that the KardiaMobile output “matches what a cardiologist expects to see on paper,” which is why it’s the most commonly recommended OTC device in clinical contexts.
Total cost of ownership: The device itself is the main cost ($149). The companion KardiaApp is free for basic recordings. A KardiaCare subscription ($99/year as of early 2026) unlocks AI interpretation history, unlimited storage, and a remote cardiologist review service. For patients who only need occasional recordings to bring to appointments, the free tier is often sufficient. No consumables, no replacement pads.
Where it falls short: The six-lead method requires you to be seated and still, placing both thumbs on the device and one leg on a third electrode. It’s not continuous — you record 30-second strips on demand. That means it will miss an arrhythmia that isn’t happening during a recording session.
Wellue DuoEK (~$199–$229)
The DuoEK captures a two-lead ECG and is notable for offering both on-demand recordings and a longer-wear chest-patch mode (up to 24 hours in some configurations). That positions it between a traditional spot-check device and a proper Holter monitor.
FDA clearance status: Yes. Wellue (also marketed under the Viatom brand) holds FDA clearance for the DuoEK. The device produces a standard ECG PDF exportable for physician review.
The tradeoff vs. the 6L: Two leads versus six is a real diagnostic limitation. Your cardiologist gets less information per recording. However, if your symptoms are intermittent and you need extended monitoring, the DuoEK’s ability to record continuously over hours is a meaningful advantage the KardiaMobile 6L cannot match.
Owners consistently report (across aggregated Amazon and health-tech forum reviews) that the chest-patch adhesive lasts reliably through a full 24-hour wear, though replacement patches (~$15–$25 for a pack) are a recurring cost to factor in for frequent users.
Emay EMG-10 (~$109–$139)
The Emay EMG-10 is a single-channel portable Holter-style recorder that captures continuous ECG over 24–72 hours and stores the data on-device for physician review. It’s the most “clinical in spirit” of the consumer-accessible options because extended Holter monitoring is the standard-of-care tool cardiologists use to capture infrequent arrhythmias.
FDA clearance status: Yes. The Emay EMG-10 holds FDA clearance as a portable ECG recorder.
What makes it different: The output is a multi-hour continuous ECG strip — not a 30-second snapshot. A cardiologist can scroll through the full recording looking for events. Per Mayo Clinic’s overview of Holter monitoring, the clinical value of extended recording comes specifically from its ability to capture arrhythmias that don’t happen on cue. The Emay provides that capability at a fraction of the cost of a prescribed Holter rental.
The honest limitation: The Emay’s AI analysis software is more basic than AliveCor’s. Reviewers at PCMag and in aggregated user feedback consistently note that the value is in handing the raw recording to your physician rather than relying on the device’s own interpretation. It’s a recording tool first, an analysis tool second.
Total cost of ownership: Device purchase is the main cost. Replacement electrodes/lead wires are inexpensive (~$10–$20 per set). No subscription required for basic recording and export.
By the Numbers
| Device | Leads | Max Recording | FDA Cleared | Cardiologist PDF | Est. Annual Cost |
|---|---|---|---|---|---|
| KardiaMobile 6L | 6-lead | 30 sec (on-demand) | ✅ Yes | ✅ Standard format | ~$149 device + $0–$99/yr app |
| Wellue DuoEK | 2-lead | Up to 24 hr patch | ✅ Yes | ✅ Exportable PDF | ~$199 device + ~$30–$60/yr patches |
| Emay EMG-10 | 1-lead (continuous) | 24–72 hr | ✅ Yes | ✅ Raw + report | ~$109–$139 device + ~$20/yr electrodes |
| Apple Watch ECG | 1-lead | 30 sec (on-demand) | ✅ Yes | ⚠️ Varies by practice | $399–$799 watch |
Sources: manufacturer published specifications; FDA 510(k) database; PCMag best ECG monitors roundup. Prices reflect May 2026 retail estimates.
What Actually Determines Cardiologist Acceptance
Clearance is necessary but not sufficient. Three additional factors determine whether a recording lands in your chart or gets politely ignored:
1. Output format. Cardiologists are trained to read standard ECG grid paper — 25mm/sec sweep speed, specific amplitude calibration. The KardiaMobile 6L and Emay are both designed to produce output in this format. The Apple Watch PDF is a valid ECG but formatted differently; acceptance is practice-dependent.
2. Lead configuration. A 2023 review published in PubMed (NCBI PMC) on single-lead ECG device validation found that single-lead recordings are reliable for AFib detection specifically, but cardiologists evaluating for other arrhythmias — ventricular ectopy, ST changes, conduction abnormalities — need more leads. If you’re monitoring for AFib only, a single-lead device clears the bar. If your cardiologist is chasing something else, six leads matters.
3. The conversation you have before you buy. This is the single most underrated factor. Call your cardiologist’s office and ask: “Which at-home ECG devices do you accept recordings from?” Many practices have a preferred workflow. Some are enrolled in AliveCor’s clinical partnership program. Some want raw data files. The answer to that question is worth more than any spec comparison.
The Decision Rule
Here’s the clean version:
-
If you have documented AFib and your cardiologist wants spot-check recordings to bring to appointments: The KardiaMobile 6L is the standard answer. Its six-lead output, FDA clearance, and clinical-format PDF make it the most universally accepted device, per PCMag’s category analysis and Wareable’s review. Budget ~$149 upfront, free app for occasional use.
-
If your symptoms are intermittent and you need extended monitoring: The Wellue DuoEK (patch mode) or Emay EMG-10 (Holter-style) is the right tool. The Emay wins on cost and duration; the DuoEK wins on analysis features and two-lead coverage. Either way, confirm with your physician that they’ll accept the output format before you buy.
-
If you own an Apple Watch and your cardiologist is comfortable with its output: You may not need a separate device at all. Ask first.
-
If you’re managing a condition that requires cardiologist-grade evidence on a recurring basis: Budget for the KardiaCare subscription on top of the 6L hardware. The remote physician review feature is the closest thing to a clinical safety net available outside a prescribed monitoring program.
The bottom line is that FDA clearance opens the door. But the device your cardiologist will actually open a PDF from depends on lead count, output format, and what your specific practice has built a workflow around. Call before you buy. It’s a two-minute conversation that protects a $150–$200 purchase decision.